Table 3 Sensitivity, specificity, PPV, NPV, and accuracy of serum FGF19 levels and the existing markers alone and in combination in small HCC cases
From: Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) | |
|---|---|---|---|---|---|
Single marker | |||||
AFP | 30.4 | 96.5 | 80.7 | 74.1 | 74.9 |
DCP | 33.3 | 95.5 | 79.3 | 73.4 | 71.1 |
FGF19 | 55.0 | 95.1 | 84.4 | 79.9 | 82.0 |
Double markers | |||||
AFP and DCP | 53.6 | 91.7 | 77.1 | 79.2 | 75.4 |
AFP and FGF19 | 68.1 | 91.5 | 79.7 | 85.5 | 83.9 |
DCP and FGF19 | 66.7 | 91.0 | 79.3 | 84.0 | 79.1 |
Multiple markers | |||||
AFP, DCP, and FGF19 | 75.4 | 87.2 | 75.3 | 87.2 | 80.1 |